- Home
- A-Z Publications
- Current Topics in Medicinal Chemistry
- Previous Issues
- Volume 12, Issue 4, 2012
Current Topics in Medicinal Chemistry - Volume 12, Issue 4, 2012
Volume 12, Issue 4, 2012
-
-
Editorial [ Hot Topic:The Indolylglyoxylamide Scaffold as an Useful Tool to Obtain Anxiolytic Agents (Guest Editors: Sabrina Taliani & Federico Da Settimo )]
Authors: Sabrina Taliani and Federico Da SettimoThe Guest Editors would like to dedicate this issue to the memory of Prof. Antonio Da Settimo. His studies on the indole nucleus, which he began in 1959, paved the way for the development of indolglyoxylamides as a class of molecules with interesting biological activity. This field has been a major topic of research for our team for over 30 years and it continues to be so today. The members of the research group founded by Read More
-
-
-
Treatment Strategies of Obsessive-Compulsive Disorder and Panic Disorder/Agoraphobia
Authors: Donatella Marazziti, Marina Carlini and Liliana Dell'OssoAnxiety disorders represent the most prevalent psychiatric disorders. In addition, a considerable burden is associated with them, not only for individual sufferers, but also for the health care system. However, many patients who might benefit from treatment are not diagnosed or treated. This may partly be due to lack of awareness of the anxiety disorders by primary care practitioners and by the sufferers themselves. In a Read More
-
-
-
The GABAA-BZR Complex as Target for the Development of Anxiolytic Drugs
Authors: Maria Letizia Trincavelli, Eleonora Da Pozzo, Simona Daniele and Claudia MartiniAnxiety disorders have been linked to alterations in γ-aminobutyric acid (GABA) neurotransmission. GABA interacts with the ligand-gated ion channels, GABAA receptor (GABAA-R) subtypes, and regulates the flow of chloride into the cell, causing neuron hyperpolarization. GABAA-Rs are assembled from a family of 19 homologous subunit gene products and form mostly hetero-oligomeric pentamers. The major isoforms o Read More
-
-
-
Translocator Protein as a Promising Target for Novel Anxiolytics
Authors: Barbara Costa, Eleonora Da Pozzo and Claudia MartiniNeurosteroids are able to rapidly control the excitability of the central nervous system, acting as regulators of type A receptors for GABA. Over the last two decades, many authors have confirmed that neurosteroid level alterations occur in psychiatric disorders, including anxiety disorders. More recently, investigators have manipulated neurosteroidogenesis in an effort to correct neuronal excitation and inhibition imbalances, whic Read More
-
-
-
Medicinal Chemistry of Indolylglyoxylamide GABAA/BzR High Affinity Ligands: Identification of Novel Anxiolytic/Non Sedative Agents
The classical benzodiazepines (Bz) constitute a well-known class of therapeutics displaying hypnotic, anxiolytic and anticonvulsant effects acting upon a specific binding site (BzR) belonging to the GABAA receptor complex. Their usefulness, however, is limited by a broad range of side effects; consequently the fact that the action of GABA with the receptor complex could be allosterically modulated by a wide variety of chemical Read More
-
-
-
Geometrically Constrained Derivatives of Indolylglyoxylamides as Ligands Binding the GABAA/BzR Complex
Authors: S. Sartini, M. Morelli, F. Simorini, S. Taliani, S. Salerno, A. M. Marini, F. Da Settimo and C. La MottaIndolylglyoxylamides are a class of distinctive benzodiazepine receptor ligands, proposed in the mid-eighties as open analogues of -carbolines. Thorough and long-lasting studies of their structure-activity relationships led to the development of a great deal of derivatives, to satisfy increasingly structural and pharmacophoric requirements of the benzodiazepine binding site in the central nervous system. Efforts to pr Read More
-
-
-
From the Pharmacophore to the Homology Model of the Benzodiazepine Receptor: The Indolyglyoxylamides Affair
Authors: Barbara Cosimelli, Sandro Cosconati, Luciana Marinelli, Ettore Novellino and Giovanni GrecoInteraction between the so-called benzodiazepine receptor (BzR) and the chemically heterogeneous class of its ligands is still one of the most challenging objects of theoretical studies. In the mid-90s our group began to collaborate with Prof. Antonio Da Settimo and coworkers to a project of synthesis and biological evaluation of indolylglyoxylamides designed as BzR ligands. Herein we review our efforts in designing these c Read More
-
-
-
Medicinal Chemistry of Indolylglyoxylamide TSPO High Affinity Ligands with Anxiolytic-Like Effects
The mitochondrial translocator protein (TSPO) mediates the synthesis of neurosteroids in the CNS, which have been demonstrated to enhance the neurotransmitter GABA response, exhibiting related behavioural properties. Selective TSPO ligands are able to stimulate steroidogenesis with great efficacy, thus representing potential anxiolytic agents. This review describes the development of a class of high affinity ligands to TSPO, Read More
-
-
-
Computational Studies on Translocator Protein (TSPO) and its Ligands
Authors: Gabriella Ortore, Tiziano Tuccinardi and Adriano MartinelliThe Translocator Protein (18 kDa) (TSPO), previously known as the peripheral benzodiazepine receptor, is widely expressed in glial cells and in peripheral tissues and is involved in a variety of biological processes: steroidogenesis, cell growth and differentiation, apoptosis induction, etc. TSPO basal expression is up-regulated in a number of human pathologies, including a variety of tumors and neuropathologies, such as glioma Read More
-
-
-
Recent Developments in Potential Anxiolytic Agents Targeting GABAA/BzR Complex or the Translocator Protein (18kDa) (TSPO)
Authors: Caroline Nothdurfter, Rainer Rupprecht and Gerhard RammesAnxiety disorders are frequent and disabling disorders. For short-term treatment, benzodiazepines are useful due to their rapid onset of anxiolytic action. However, these compounds have sedative properties and may induce tolerance, abuse liability and withdrawal symptoms. First-line choices for the long-term treatment are selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. The major disad Read More
-
Volumes & issues
-
Volume 25 (2025)
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
-
Volume 5 (2005)
-
Volume 4 (2004)
-
Volume 3 (2003)
-
Volume 2 (2002)
-
Volume 1 (2001)
Most Read This Month
Article
content/journals/ctmc
Journal
10
5
false
en
